Quell Introduction
Find out more about our vision to bring truly innovative, life changing Treg therapies for our patients as we build a major global biopharmaceutical company as well as what it’s like to work for Quell.
Quell Therapeutics is a London, UK based, private biopharmaceutical company. Our vision is to be the leading engineered cell therapy company, bringing transformational and valued therapies addressing a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation.
Quell was founded in partnership with six world leading experts in the field of immunology from King’s College London, University College London and Hannover Medical School. The Founders have made a significant contribution in the field of Immunology in understanding how to harness the suppressive capacity of Tregs in order to address immune dysfunction by utilising engineered Tregs.
Learn more about how we are developing transformational therapies using modular engineered Treg cell therapies for the treatment of a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation.
We are developing therapies addressing a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation. Learn more about our pipeline of products in development.
Quell is a culture-led organisation which LIVES its values and we respect the diverse qualities our employees bring. Learn more about working with us.
Collaboration will accelerate Quell’s pipeline expansion into neuroinflammatory diseases London and Sheffield, UK – October 26, 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative…...
Read MoreLondon – June 11 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the appointments of seasoned industry expert, Dr Dhaval Patel, Executive Vice President and Chief Scientific Officer UCB S.A. (Brussels, Belgium),…...
Read MoreCollaboration will accelerate Quell’s pipeline expansion into autoimmune and inflammatory diseases London and Hannover – April 7 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a…...
Read More